Predictive biomarkers for immunotherapy in non-small cell lung cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Reck, MD, PhD, from the LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses immunotherapy as an option for patients with non-small cell lung cancer (NSCLC) who progress after initial treatment, as well as programmed death-ligand 1 (PD-L1) expression as a predictive biomarker for the development of immunotherapy.